Post-Market Surveillance

« Back to Glossary Index

What it is

Post-Market Surveillance (PMS) is the ongoing, systematic collection and analysis of data about a device or IVD after market entry to confirm safety, performance, and benefit-risk over time. PMS turns real-world feedback into actions such as updates, CAPA, and—when needed—recalls (MDR/IVDR Chapter VII; FDA 21 CFR 803/806/822; ISO 13485 §8; ISO 14971).

Lifecycle: After launchFocus: Safety & performanceOutputs: Reports • CAPA • Updates

Regulatory framework

  • EU (MDR/IVDR): PMS system and plan (MDR Art. 83–86; IVDR Art. 78–81); PMS Report (Class I) and PSUR (higher classes); PMCF where needed (MDR Annex XIV Part B); trend reporting and vigilance (MDR Arts. 87–92; IVDR Arts. 82–87); technical documentation updates (Annex II–III).
  • US (FDA): Medical Device Reporting (21 CFR 803); corrections/removals (21 CFR 806); postmarket surveillance studies when ordered (21 CFR 822); recalls policy (21 CFR 7, guidance); quality records under 21 CFR 820 (QMSR).
  • Canada: Mandatory Problem Reporting (SOR/98-282 §§59–61); recalls and records (§§57–65); license conditions and ongoing compliance.
  • Japan (PMDA/MHLW): Good Vigilance Practice (MHLW Ordinance No. 135/2004) and PMD Act reporting; coordination with QMS Ordinance (No. 169/2004).
  • Australia (TGA): Incident reporting and recalls under Therapeutic Goods (Medical Devices) Regulations 2002 (e.g., r. 5.7–5.8); ongoing ARTG obligations.

Key elements

  • PMS plan: Data sources, methods, responsibilities, and triggers for action.
  • Data inputs: Complaints, service data, literature, registries, user feedback, manufacturing trends, and competitor signals.
  • PMCF/clinical follow-up: Targeted studies or evaluations to address residual risks and new questions (MDR Annex XIV Part B).
  • Reporting: PMS Report/PSUR (EU), MDR/eMDR submissions (US 21 CFR 803), and recalls or corrections (21 CFR 806; EU vigilance).
  • Coding & trending: IMDRF event/problem codes, UDI use, and statistical thresholds for escalation (MDR Art. 88).

Process — how it works

  • Plan: Define the PMS plan and success criteria; align with intended purpose and risk files.
  • Collect: Aggregate data continuously from defined sources; verify validity and completeness.
  • Analyze: Trend events, detect signals, and assess benefit-risk; then decide if action is needed.
  • Act: File required reports, initiate CAPA or field actions, and update labeling or IFU as needed.
  • Report: Issue PMS Report/PSUR on schedule; document rationales and outcomes.
  • Improve: Feed results into risk management, design changes, and management review.

Common pitfalls

  • Collecting data without clear thresholds or trend rules, so signals arrive late.
  • Missing vigilance timelines (e.g., EU 2/10/15-day windows; US 30-day and 5-day reports).
  • Weak linkage between PMS, CAPA, and risk files (ISO 14971), which slows fixes.
  • PSUR content that does not reflect real complaint and performance data.
  • Ignoring literature and external sources, therefore losing early warning signs.

Quick checks

  • Is the PMS plan current, risk-based, and approved?
  • Are IMDRF codes, UDI, and statistical rules used for trending?
  • Do PSUR/PMS Reports match source data and support current labeling?
  • Are vigilance and recall packages pre-staged to meet deadlines?

FAQ

Is PMS mandatory?

Yes. EU MDR/IVDR require a PMS system and plan (Arts. 83–86/78–81). FDA requires ongoing complaint handling, MDR reporting (21 CFR 803), and corrections/removals (21 CFR 806); it may order 21 CFR 822 studies.

What is the difference between PMS and vigilance?

PMS is the broad system for monitoring and improvement; vigilance is the subset of reportable incidents, malfunctions, and field actions with strict timelines and formats.

When is a PSUR required?

In the EU, higher-class devices and many IVDs must submit a PSUR at set intervals; Class I uses a PMS Report (MDR Art. 86; IVDR Art. 81).

Do all events need to be reported to authorities?

No. Report only events that meet criteria. However, trend reporting and internal CAPA may still be required even when external reporting is not.

How does PMS link to labeling and claims?

PMS findings may trigger labeling updates, IFU changes, or new warnings; ensure changes are controlled and consistent with risk management and regulatory files.